Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Causing Implausible Speculation, With No Responsibilty
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2261)
•••
Comment by Boomskidon Feb 22, 2023 11:57pm
76 Views
Post# 35299944

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Causing Implausible Speculation, With No Responsibilty

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Causing Implausible Speculation, With No ResponsibiltyI'm not saying that debt-holders are trying to steal xB3. I'm saying that Midatech and Armistice are trying to buy it with the help of Ladenburg Thalmann, who also get a piece of it. Lind, the debt holder, loaned money to Bioasis on the strength of the value of xB3.

Zwerp, you're being unequivocal in your statements that xB3 is worthless and you're doing so without considering that others who know a lot more than you are placing value on it. You're disregarding the probability that there was a standstill placed on Bioasis deals when Ladenburg Thalmann got involved a year and a half ago or so. It's possible that Bioasis had deals available to them but postponed them while they were setting up this awful deal. What was Ellipses, anyway? It's another reason why an investigation is needed. Bioasis may have purposefully prevented deals from getting done and they could get away with it by saying that they were setting up a "merger" that required a standstill!

No matter what, somebody wants xB3 and I fully believe that deals can be done with it.

We know that you want to get your emotional rocks off here but you're not using available information and logical thought about it.

jd
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities